Wave of Acquisitions Hits ADC Cancer Treatment Space
The end of 2020 saw several big pharma acquisitions of companies developing antibody-drug conjugate drugs…
The end of 2020 saw several big pharma acquisitions of companies developing antibody-drug conjugate drugs…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York…
Try as we might, we can’t cover every bit of news out there. So relax…
The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO,…
Two companies based in Lausanne, Switzerland -- ADC Therapeutics and the genomics company SOPHiA Genetics…
Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M)…
The Swiss city of Lausanne is perhaps best known as a hub of international sport,…
Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where…
ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech…
Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with…
ADC Therapeutics has presented preliminary Phase I data in lymphoma patients suggesting its ADC technology…